Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Vanway Pharmaceutical Holdings
Rugao, Jiangsu, China
- Ownership
- Private
- Development stage
- Other
01
Overview
Vanway Pharmaceutical Holdings develops and manufactures biological drugs. Its lead product Analgecine (“Extracts from Rabbit Skin Inflamed by Vaccinia Virus for Injection”) has been approved in China since December 2003 as a treatment for neuralgia and various forms of musculoskeletal pain. The drug acts via modulation of serotonin receptors and antagonism of bradykinin receptors. It remains under clinical investigation for expanded indications including intervertebral disc disease and acute ischemic stroke. The company’s manufacturing operations are based in Rugao, Jiangsu province.
- Therapeutic areas
- RheumatologyNeurologyCardiovascular
- Modalities
- Biological productsSmall molecule
- Industry
- Biotech
Beyond the preview
Go deeper on Vanway Pharmaceutical Holdings.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Vanway Pharmaceutical Holdings.